0
0
Revolutionizing Dentistry with Genetically Engineered Bacteria
About seven years ago, Aaron Silverbook and his then-girlfriend, a biologist, were in the midst of a romantic evening perusing old scientific literature online. During their exploration, Silverbook stumbled upon a study from 2000 that left him astounded. The study detailed the genetic engineering of an oral bacterium which had the potential to prevent tooth decay. This incredible discovery led Silverbook to wonder why such a groundbreaking development had not yet been widely implemented.
Motivated by curiosity and a desire to advance dental health, Silverbook took it upon himself to track down the primary author of the study, Jeffrey Hillman, a retired oral biologist formerly associated with the University of Florida. Their subsequent collaboration and combined efforts paved the way for the establishment of Lantern Bioworks in 2023. Through a partnership with Oragenics, the company co-founded by Hillman and holding the rights to the technology, Lantern Bioworks introduced genetically engineered bacteria under the name Lumina Probiotic.
Jeffrey Hillman expressed his disbelief at the rapid progress, admitting, “I didn’t expect it to happen in my lifetime.” The product garnered attention last month, boasting claims of cavity prevention. A press kit promoted Lumina as a revolutionary solution, suggesting that a single application of the genetically modified bacteria could indefinitely protect against dental cavities.
A Shift in Priorities and Messaging
With the product now available for pre-order, notable changes have been observed in the brand’s messaging. The language pertaining to cavity prevention has been noticeably altered, and the press kit containing assertive claims has since been removed from the website. Aaron Silverbook, despite lacking a professional background in dentistry or microbiology, attributes this shift to legal advice. Lantern Bioworks is now positioning Lumina as a cosmetic product, a strategic move allowing freedom from stringent regulatory trials imposed on medicinal drugs.
The application process for Lumina is relatively straightforward, involving a one-time procedure that can be administered either by individuals at home or by dental professionals. Additional applications are recommended to enhance the bacteria’s inoculation efficiency. According to Silverbook, the company is aiming to commence shipping Lumina by mid-June.
Challenges and Ethical Considerations
Despite the company’s optimism, experts within the scientific community have raised valid concerns regarding the safety and ethical implications of Lumina. Notably, the absence of human clinical trials has sparked skepticism among professionals like Jennifer Kuzma, a professor at North Carolina State University’s Genetic Engineering and Society Center. Kuzma emphasized the critical importance of rigorous testing to establish both safety and efficacy before introducing such products to the public.
Furthermore, the potential alteration of the oral microbiome due to Lumina’s introduction poses unforeseen risks. Kuzma cautioned that unintended consequences, such as an increased susceptibility to cavities or other oral issues, could emerge if the treatment is not thoroughly evaluated through clinical trials.
Another ethical dilemma revolves around the possible transmission of Lumina between individuals. The lack of data regarding interpersonal spread raises concerns about informed consent. Individuals who have not received the treatment but come into close contact with those who have may inadvertently encounter the genetically engineered bacteria, leading to unforeseeable consequences.
Moreover, the ambiguity surrounding the product’s classification as either cosmetic or medicinal further complicates the regulatory landscape. Kuzma highlighted the regulatory system’s inadequacies in addressing novel products like Lumina, underscoring the need for clarity and stringent oversight in this evolving field.
Image/Photo credit: source url
